Arrowhead Research Corp. (ARWR) Reports In-Line Q3 EPS, Provides Update on ARC-520
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Arrowhead Research (ARWR) Sees Early Upside
August 14, 2014 9:44 AM EDTArrowhead Research (NASDAQ: ARWR) seeing strong morning upside on solid volume. Shares are up 7%.
Deutsche Bank Maintains Buy Rating on Arrowhead Research (ARWR)
August 13, 2014 9:58 AM EDTDeutsche Bank maintained a Buy rating on Arrowhead Research (NASDAQ: ARWR) with a price target of $45. Comments follow its ARC-520 update.
Analyst Alethia Young said, "We feel more confident in ARC-520 and their platform technology after this interim update. Safety looks solid... More
Arrowhead Research (ARWR) Bullish Stance Reiterated at Jefferies as ARC-520 Shows Highly Encouraging Efficacy
August 13, 2014 6:52 AM EDTJefferies analyst Thomas Wei reiterated a Buy rating and $30 price target on Arrowhead Research (NASDAQ: ARWR) as ARC-520 shows highly encouraging efficacy.
Wei commented, "ARWR provided an update from its Phase 2a trial, in which patients receiving a single dose of ARC-520... More



